RCUS Arcus Biosciences Inc.

13.97
+0.09  (+1%)
Previous Close 13.88
Open 13.8
Price To Book 3.92
Market Cap 642,259,420
Shares 45,974,189
Volume 259,310
Short Ratio 1.75
Av. Daily Volume 379,158
Stock charts supplied by TradingView

NewsSee all news

  1. Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

    CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) --

  2. Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors

  3. Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019

    CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  4. Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

    - Advanced three molecules into randomized Phase 2 trials to evaluate Arcus's potential best-in-class therapies and highly differentiated therapeutic combinations; Preliminary randomization data expected in 4Q20 for

  5. Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho's Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries

    Taiho's in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus's and Taiho's oncology portfolios Zimberelimab exhibits clinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 dose-expansion cohort to be initiated mid-2019.
Zimberelimab (AB122)
Healthy volunteers
Phase 1 initiation announced September 4, 2019.
AB298 + IPI-549 + Doxil
Triple negative breast cancer (TNBC) and ovarian cancer
Phase 1 ongoing.
AB928 + mFOLFOX
Colorectal Cancer
Phase 1b expansion data due from mid-2020.
AB928 + Zimberelimab (AB122)
Solid tumors
Phase 2 randomization data due 4Q 2020
AB154 + Zimberelimab (AB122) (ARC-7)
Non-small cell lung cancer (NSCLC)
Phase 1 expansion data due mid-2020. Phase 1b expansion cohort anticipated to start in mid-2020.
AB680 +Zimberelimab (AB122)
Pancreatic Cancer

Latest News

  1. Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

    CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) --

  2. Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors

  3. Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019

    CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today

  4. Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

    - Advanced three molecules into randomized Phase 2 trials to evaluate Arcus's potential best-in-class therapies and highly differentiated therapeutic combinations; Preliminary randomization data expected in 4Q20 for

  5. Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho's Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries

    Taiho's in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus's and Taiho's oncology portfolios Zimberelimab exhibits clinical

  6. Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global

  7. Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

    Collaboration leverages Genentech's MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer Arcus Biosciences,

  8. Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates

    Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A2a and A2b receptors, as evidenced by a favorable safety profile when combined with multiple

  9. Arcus Biosciences Appoints Internationally Distinguished Physician-Scientist, Antoni Ribas, M.D., Ph.D., to Board of Directors

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Company's Board of

  10. Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

    Company to participate in poster display session on September 30, 2019 at 12:00pm CEST Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies,

  11. Arcus Biosciences to Present at the 2019 Cantor Global Healthcare Conference

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019